A Pivotal Investigational Device Exemption Study on Laminar Left Atrial Appendage Elimination

Inclusion Criteria: * Documented evidence of paroxysmal, persistent, or permanent non-valvular atrial fibrillation (NVAF) * CHA2DS2-VASc score greater than or equal to (\>=) 2 in men and \>= 3 in women * Deemed to be clinically indicated for left atrial appendage (LAA) closure by the Site Investigator and a clinician not a part of the procedural team using an evidence-based decision-making tool in accordance with standard of care * Recommended for chronic oral anticoagulation therapy (OAC) but has an appropriate rationale to seek a non-pharmacologic alternative * Eligible for the protocol-specified post-procedural antithrombotic regimen * Willing and able to comply with the protocol, and has provided written informed consent (participant or legally authorized representative) per institutional review board (IRB) requirements Exclusion Criteria: * Single episode, transient, or reversible atrial fibrillation (AF) (example, secondary to thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures) * Prior cardiac surgery or any procedure that involved pericardial access * Stage IV kidney disease or Renal insufficiency, defined as estimated glomerular filtration rate (eGFR) less than (\<) 30 milliliters per minute per (mL/min)/1.73 square meters (m\^2) or participants with end stage renal disease who are dialysis dependent * Any cardiac or non-cardiac interventional or surgical procedures within 60 days prior to or any planned general surgery, cardiac…